Ph-positive acute lymphoblastic leukemia
Conditions
Interventions
Case series:dasatinib
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
16 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years old male and female; 2. Confirmed Ph positive acute lymphoblastic leukemia (see WHO Hematopoietic and Lymphatic Tumor Pathology and Genetics) requiring positive BCR/ABL fusion gene and / or Ph1 chromosome t(9; 22) (q34; q11) ; 3. Hepatitis B surface antigen negative, HBsAg positive patients need HBV-DNA <1×10^3 copy/ml; 4. Liver function: ALT < 2 times the upper limit of normal, AST < 2 times the upper limit of normal; 5. normal renal function; 6. Hepatitis B virus surface antigen is negative, positive surface antigen or HBV-DNA replication are active, need antiviral therapy.
Exclusion criteria
Exclusion criteria: 1. ECOG score> 2; 2. Previous history of drugs (dasatinib, dasatinib, and nilotinib) targeting at BCR/ABL fusion genes; 3. Serious heart, lung, kidney disease, or the any other life threatening condition; 4. Active gastrointestinal bleeding; 5. Lymphoblastic crisis of chronic myelogenous leukemia;; 6. Other coexisting malignancies other than cured cervical cancer; 7. Pregnant or breastfeeding patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| completer remission rate;overall survival;relaspe free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| treament related mortality; | — |
Countries
China
Contacts
Public ContactTing Liu
Department of Hematology, West China Hospital, Sichuan University
Outcome results
None listed